Tango Therapeutics TNGX Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's cash and cash equivalents, end of period?
- Tango Therapeutics (TNGX) reported cash and cash equivalents, end of period of $159.97M in Q1 2026.
- How has Tango Therapeutics's cash and cash equivalents, end of period changed year-over-year?
- Tango Therapeutics's cash and cash equivalents, end of period increased by 162.2% year-over-year, from $61M to $159.97M.
- What is the long-term trend for Tango Therapeutics's cash and cash equivalents, end of period?
- Over 5 years (2020 to 2025), Tango Therapeutics's cash and cash equivalents, end of period has grown at a 30.2% compound annual growth rate (CAGR), from $30.66M to $114.85M.